Compare NMFC & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NMFC | IMMX |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 745.2M | 736.1M |
| IPO Year | N/A | 2021 |
| Metric | NMFC | IMMX |
|---|---|---|
| Price | $7.04 | $10.63 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $8.63 | ★ $19.20 |
| AVG Volume (30 Days) | 838.3K | ★ 2.3M |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | ★ 15.27% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.51 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.80 | $1.94 |
| 52 Week High | $10.90 | $12.14 |
| Indicator | NMFC | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 39.48 | 56.13 |
| Support Level | $6.80 | $7.99 |
| Resistance Level | $7.31 | $11.87 |
| Average True Range (ATR) | 0.18 | 0.86 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 47.06 | 40.35 |
New Mountain Finance Corp is a closed-end, non-diversified management investment company. It invests in equity interests such as preferred stock, common stock, warrants, or options received in connection with debt investments or may include direct investment in the equity of private companies. The company's investment objective is to generate current income and capital appreciation through sourcing and origination of debt securities at all levels of the capital structure, including first and second-lien debt, notes, bonds and mezzanine securities.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.